Immunotherapy for Infectious Diseases

Active Immunization for HIV Infection 193
48. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody
responses in a subset of persons with stable nonprogressing HIV type 1 infection.
AIDS Res Hum Retroviruses 1996; 12:585.
49. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human
immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response
at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-
Barr virus in late disease. J Exp Med 1993; 177:249.
50. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte
responses during the clinical course of HIV-1 infection: a longitudinal analysis of
rapid progressors and long-term asymptomatics. J Exp Med 1995; 181:1365.
51. Rinaldo C, Huang XL, Fan ZF, et al. High levels of anti-human immunodeficiency virus
type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated
with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995; 69:5838.
52. Miedema F, Meyaard L, Koot M, et al. Changing virus-host interactions in the course of
HIV-1 infection [Review] [198 refs]. Immunol Rev 1994; 140:35.
53. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely
infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells [published
erratum appears in Nature 1993;364:262]. Nature 1993; 362:758.
54. Pantaleo G, Soudeyns H, Demarest JF, et al. Evidence for rapid disappearance of initially
expanded HIV-specific CD8� T cell clones during primary HIV infection. Proc Natl Acad
Sci USA 1997; 94:9848.
55. Brander C, Goulder PJ, Luzuriaga K, et al. Persistent HIV-1-specific CTL clonal expansion
despite high viral burden post in utero HIV-1 infection. J Immunol 1999; 162:4796.
56. Islam SA, Hay CM, Hartman KE, et al. Persistence of human immunodeficiency virus
type 1-specific cytotoxic T-lymphocyte clones in a subject with rapid disease progression.
J Virol 2001; 75:4907.
57. Abbas AK. Die and let live: eliminating dangerous lymphocytes. Cell 1996; 84:655.
58. Hay CM, Ruhl DJ, Basgoz NO, et al. Lack of viral escape and defective in vivo activation
of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly
progressive infection. J Virol 1999; 73:5509.
59. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic
T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL
escape virus. Nat Med 1997; 3:205.
60. Koenig S, Conley AJ, Brewah YA, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes
to an AIDS patient leads to selection for mutant HIV variants and subsequent disease
progression. Nat Med 1995; 1:330.
61. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic
T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212.
62. Kalams SA, Johnson RP, Dynan MJ, et al. T cell receptor usage and fine specificity of
human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: analysis of quasispecies
recognition reveals a dominant response directed against a minor in vivo variant.
J Exp Med 1996; 183:1669.
63. Cao H, Kanki P, Sankale JL, et al. Cytotoxic T-lymphocyte cross-reactivity among different
human immunodeficiency virus type 1 clades: implications for vaccine development.
J Virol 1997; 71:8615.
64. Brander C, Yang OO, Jones NG, et al. Efficient processing of the immunodominant,
HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte
epitope despite multiple variations in the epitope flanking sequences. J Virol 1999;
73:10191.
65. Altfeld MA, Livingston B, Reshamwala N, et al. Identification of novel HLA-A2-restricted
human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted
by the HLA-A2 supertype peptide-binding motif. J Virol 2001; 75:1301.